Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

BACKGROUND: Acquired epidermal growth factor receptor (EGFR) T790M mutation is the primary resistance mechanism to first-generation EGFR tyrosine kinase inhibitors (TKIs) used in advanced, EGFR mutation-positive non-small-cell lung cancer (NSCLC). Available data, predominantly in Asian patients, sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochmair, Maximilian J., Buder, Anna, Schwab, Sophia, Burghuber, Otto C., Prosch, Helmut, Hilbe, Wolfgang, Cseh, Agnieszka, Fritz, Richard, Filipits, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403194/
https://www.ncbi.nlm.nih.gov/pubmed/30539501
http://dx.doi.org/10.1007/s11523-018-0612-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403194/
https://www.ncbi.nlm.nih.gov/pubmed/30539501
http://dx.doi.org/10.1007/s11523-018-0612-z

Ejemplares similares